Sakar Healthcare Limited (SAKAR.NS)
INR 310.45
(-0.34%)
INR 310.45
(-0.34%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 1.26 Billion INR | -22.49% |
| 2022 | 1.62 Billion INR | 16.17% |
| 2021 | 1.4 Billion INR | 76.83% |
| 2020 | 793.4 Million INR | 134.71% |
| 2019 | 338.03 Million INR | 25.29% |
| 2018 | 269.81 Million INR | -8.87% |
| 2017 | 296.07 Million INR | -15.61% |
| 2016 | 350.84 Million INR | 9.89% |
| 2015 | 319.27 Million INR | -9.68% |
| 2014 | 353.47 Million INR | -8.11% |
| 2013 | 384.65 Million INR | 1.29% |
| 2012 | 379.74 Million INR | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | -2.62 Billion INR | -307.66% |
| 2024 Q2 | 1.34 Billion INR | 151.39% |
| 2023 FY | 1.32 Billion INR | -18.48% |
| 2023 Q1 | - INR | -100.0% |
| 2023 Q4 | 1.26 Billion INR | 0.0% |
| 2023 Q2 | 1.2 Billion INR | 0.0% |
| 2023 Q3 | - INR | -100.0% |
| 2022 Q2 | 1.42 Billion INR | 0.0% |
| 2022 Q3 | - INR | -100.0% |
| 2022 Q1 | - INR | -100.0% |
| 2022 FY | 1.62 Billion INR | 16.17% |
| 2022 Q4 | 1.62 Billion INR | 0.0% |
| 2021 FY | 1.4 Billion INR | 76.83% |
| 2021 Q4 | 1.4 Billion INR | 0.0% |
| 2021 Q2 | 1.06 Billion INR | 0.0% |
| 2021 Q3 | - INR | -100.0% |
| 2020 FY | 793.4 Million INR | 134.71% |
| 2020 Q1 | - INR | -100.0% |
| 2020 Q4 | 793.4 Million INR | 0.0% |
| 2020 Q2 | 575.53 Million INR | 0.0% |
| 2020 Q3 | - INR | -100.0% |
| 2019 Q4 | 338.03 Million INR | 0.0% |
| 2019 FY | 338.03 Million INR | 25.29% |
| 2019 Q1 | - INR | -100.0% |
| 2019 Q2 | 299.49 Million INR | 0.0% |
| 2019 Q3 | - INR | -100.0% |
| 2018 Q1 | - INR | -100.0% |
| 2018 Q2 | 310.29 Million INR | 0.0% |
| 2018 Q4 | 269.81 Million INR | 0.0% |
| 2018 FY | 269.81 Million INR | -8.87% |
| 2017 FY | 296.07 Million INR | -15.61% |
| 2017 Q4 | 296.07 Million INR | 0.0% |
| 2017 Q2 | 372.9 Million INR | 0.0% |
| 2016 Q4 | 350.84 Million INR | 0.0% |
| 2016 FY | 350.84 Million INR | 9.89% |
| 2015 Q1 | 365.36 Million INR | 3.37% |
| 2015 Q4 | 319.27 Million INR | -5.97% |
| 2015 Q2 | 365.36 Million INR | 0.0% |
| 2015 FY | 319.27 Million INR | -9.68% |
| 2015 Q3 | 339.53 Million INR | -7.07% |
| 2014 FY | 353.47 Million INR | -8.11% |
| 2014 Q4 | 353.46 Million INR | 0.0% |
| 2013 FY | 384.65 Million INR | 1.29% |
| 2012 FY | 379.74 Million INR | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Sigachi Industries Limited | 2.53 Billion INR | 50.093% |
| Ind-Swift Limited | 13.45 Billion INR | 90.61% |
| Bajaj HealthCare Limited | 4.86 Billion INR | 74.048% |
| Aurobindo Pharma Limited | 152.2 Billion INR | 99.17% |
| Innova Captab Limited | 4.89 Billion INR | 74.218% |
| Divi's Laboratories Limited | 18.99 Billion INR | 93.348% |
| AstraZeneca Pharma India Limited | 3.66 Billion INR | 65.495% |
| Morepen Laboratories Limited | 4.45 Billion INR | 71.674% |
| Mankind Pharma Limited | 23.87 Billion INR | 94.709% |
| Sequent Scientific Limited | 8.27 Billion INR | 84.732% |
| Wanbury Limited | 3.15 Billion INR | 59.966% |
| Laurus Labs Limited | 42.71 Billion INR | 97.043% |
| Nectar Lifesciences Limited | 11.21 Billion INR | 88.739% |
| Glenmark Life Sciences Limited | 5.18 Billion INR | 75.617% |
| Alembic Limited | 1.43 Billion INR | 11.788% |
| Hikal Limited | 12.99 Billion INR | 90.279% |
| Alembic Pharmaceuticals Limited | 16.27 Billion INR | 92.237% |
| Neuland Laboratories Limited | 5.49 Billion INR | 77.025% |
| J. B. Chemicals & Pharmaceuticals Limited | 10.7 Billion INR | 88.202% |
| Glenmark Pharmaceuticals Limited | 65.11 Billion INR | 98.06% |
| IOL Chemicals and Pharmaceuticals Limited | 6.32 Billion INR | 80.04% |
| Themis Medicare Limited | 1.88 Billion INR | 33.072% |
| RPG Life Sciences Limited | 1.38 Billion INR | 8.471% |
| Zydus Lifesciences Limited | 71.79 Billion INR | 98.24% |
| Lupin Limited | 96.23 Billion INR | 98.687% |
| Amrutanjan Health Care Limited | 783.82 Million INR | -61.169% |
| Wockhardt Limited | 39.87 Billion INR | 96.832% |
| Vaishali Pharma Limited | 371.16 Million INR | -240.357% |
| Aarti Pharmalabs Limited | 8.25 Billion INR | 84.689% |
| Jagsonpal Pharmaceuticals Limited | 296.76 Million INR | -325.691% |
| Jubilant Pharmova Limited | 61.27 Billion INR | 97.938% |
| FDC Limited | 3.7 Billion INR | 65.942% |
| Dr. Reddy's Laboratories Limited | 106.96 Billion INR | 98.819% |
| Kilitch Drugs (India) Limited | 643.88 Million INR | -96.197% |
| Eris Lifesciences Limited | 38.26 Billion INR | 96.699% |
| Venus Remedies Limited | 1.39 Billion INR | 9.299% |
| ZIM Laboratories Limited | 2.08 Billion INR | 39.288% |
| Bliss GVS Pharma Limited | 2.1 Billion INR | 40.096% |
| Par Drugs and Chemicals Limited | 159.79 Million INR | -690.583% |
| Caplin Point Laboratories Limited | 3.5 Billion INR | 63.964% |
| Shilpa Medicare Limited | 12.93 Billion INR | 90.232% |
| Albert David Limited | 1.15 Billion INR | -9.84% |
| Ajanta Pharma Limited | 10.71 Billion INR | 88.205% |
| Hester Biosciences Limited | 3.59 Billion INR | 64.857% |
| Suven Pharmaceuticals Limited | 2.03 Billion INR | 37.899% |
| Solara Active Pharma Sciences Limited | 14.09 Billion INR | 91.035% |
| Gufic Biosciences Limited | 5.59 Billion INR | 77.441% |
| Windlas Biotech Limited | 1.76 Billion INR | 28.333% |
| Procter & Gamble Health Limited | 2.56 Billion INR | 50.676% |
| Aarey Drugs & Pharmaceuticals Limited | 1.72 Billion INR | 26.647% |
| Mangalam Drugs & Organics Limited | 1.97 Billion INR | 36.079% |
| Granules India Limited | 22.95 Billion INR | 94.497% |
| Aarti Drugs Limited | 11.5 Billion INR | 89.019% |
| Bal Pharma Limited | 2.51 Billion INR | 49.696% |
| Alkem Laboratories Limited | 48.6 Billion INR | 97.401% |
| Sun Pharmaceutical Industries Limited | 183.56 Billion INR | 99.312% |
| Lincoln Pharmaceuticals Limited | 1.07 Billion INR | -17.564% |
| Medicamen Biotech Limited | 940.36 Million INR | -34.339% |
| Unichem Laboratories Limited | 8.06 Billion INR | 84.345% |
| Bafna Pharmaceuticals Limited | 652.27 Million INR | -93.672% |
| Biofil Chemicals and Pharmaceuticals Limited | 288.79 Million INR | -337.425% |
| Valiant Laboratories Limited | 1.05 Billion INR | -19.373% |
| Orchid Pharma Limited | 3.84 Billion INR | 67.137% |
| Medico Remedies Limited | 438.24 Million INR | -188.26% |
| Ind-Swift Laboratories Limited | 2.28 Billion INR | 44.822% |
| Ipca Laboratories Limited | 33.74 Billion INR | 96.256% |
| Brooks Laboratories Limited | 248.6 Million INR | -408.156% |
| Syncom Formulations (India) Limited | 1.16 Billion INR | -8.416% |
| Piramal Enterprises Limited | 560.47 Billion INR | 99.775% |
| Torrent Pharmaceuticals Limited | 82.05 Billion INR | 98.46% |
| NATCO Pharma Limited | 10.53 Billion INR | 88.005% |
| Suven Life Sciences Limited | 148.62 Million INR | -750.001% |
| Krebs Biochemicals & Industries Limited | 2.97 Billion INR | 57.521% |
| Strides Pharma Science Limited | 37.68 Billion INR | 96.647% |
| Indoco Remedies Limited | 10.34 Billion INR | 87.785% |
| Alpa Laboratories Limited | 307.12 Million INR | -311.328% |
| Lasa Supergenerics Limited | 541.92 Million INR | -133.11% |
| Sun Pharma Advanced Research Company Limited | 3.89 Billion INR | 67.549% |